

ESMO PRECEPTORSHIP PROGRAMME HEAD & NECK CANCER

Multidisciplinary management, standards of care,
therapeutic targets and future perspectives

Hong Kong
13-14 April 2019

CO-CHAIRS: Anthony T. C. Chan, Hong Kong
Jean-Pascal Machiels, Belgium

SPEAKERS: Melvin L. K. Chua, Singapore
Brigette Ma, Hong Kong
Sandra Nuyts, Belgium
Christian Simon, Switzerland
Joseph Wee, Singapore
John K. S. Woo, Hong Kong

LEARNING OBJECTIVES

- To understand epidemiology, aetiology and molecular biology of nasopharyngeal cancer and squamous cell carcinoma of the head and neck (HNSCC)
- To understand multidisciplinary management and treatment of head and neck cancer
- To learn about advances in the treatment and novel targets in head and neck cancer

Saturday, 13 April 2019

09:00-09:15 15'	Welcome and introduction	Anthony T. C. Chan, HK Jean-Pascal Machiels, BE
09:15-12:45 180'	SESSION 1 Nasopharyngeal cancer	Co-Chairs: Anthony T. C. Chan, HK Joseph Wee, SG
30'	Management of localized disease	Joseph Wee, SG
30'	Epidemiology, diagnosis and work-up	John K. S. Woo, HK
30'	Management of metastatic disease and salvage treatment	Anthony T. C. Chan, HK
30'	Molecular biology and biomarkers	Brigette Ma, HK
11:15-11:45	Coffee break	
60'	Participants clinical case discussion (4x15')	Faculty
12:45-13:45	Lunch	

13:45-18:00 225'	SESSION 2 Squamous cell carcinoma	Co-Chairs: Melvin L. K. Chua, SG Jean-Pascal Machiels, BE
60'	Indications and techniques of surgery for the primary treatment of HNSCC	Christian Simon, CH
45'	Epidemiology, anatomy and work-up	Melvin L. K. Chua, SG
15:30-16:00	Coffee break	
60'	Indications and modalities of radiation or CRT for local and locoregional disease	Sandra Nuyts, BE
60'	Participants clinical case discussion (4x15')	Faculty
19:30	Dinner	

Sunday, 14 April 2019

08:30-12:00 180'	SESSION 3 Precision medicine for head and neck cancer	Co-Chairs: Sandra Nuyts, BE Brigette Ma, HK
30'	Molecular biology and The Cancer Genome Atlas (TCGA) data	Jean-Pascal Machiels, BE
30'	Relapsing HNSCC (salvage treatment, systemic treatment and immunotherapy)	Jean-Pascal Machiels, BE
30'	Treatment specificities of Human Papillomavirus (HPV)-induced oropharyngeal cancer: The surgeon's point of view	Christian Simon, CH
30'	Treatment specificities of HPV-induced oropharyngeal cancer: The radiation oncologist's point of view	Sandra Nuyts, BE
10:30-11:00	Coffee break	
60'	Participants clinical case discussion (4x15')	Faculty
12:00-12:15 15'	Conclusion and farewell	Anthony T. C. Chan, HK Jean-Pascal Machiels, BE
12:15-13:15	Lunch	

Note: Each 15 minute slot for clinical case discussion includes 7' case presentation and 8' Q&A / panel discussion